SOUTH SAN FRANCISCO, Calif. (AP) _ CytomX Therapeutics Inc. (CTMX) on Thursday reported a loss of $14 million in its fourth quarter.
The South San Francisco, California-based company said it had a loss of 39 cents per share.
The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share.
The biopharmaceutical company posted revenue of $6.3 million in the period.
For the year, the company reported that its loss widened to $58.9 million, or $1.63 per share. Revenue was reported as $15 million.
CytomX Therapeutics shares have risen 32 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $14.50, an increase of almost 2 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CTMX at https://www.zacks.com/ap/CTMX
Keywords: CytomX Therapeutics, Earnings Report